Drug Patents owned by Eirgen

1. Drug name - RAYALDEE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9943530 EIRGEN Treating vitamin D insufficiency and deficiency with 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3 Feb, 2027

(4 years from now)

US8906410 EIRGEN Oral dosage form of 25-hydroxyvitamin D Feb, 2027

(4 years from now)

US10213442 EIRGEN Treating vitamin D insufficiency and deficiency with 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3 Feb, 2027

(4 years from now)

US8207149 EIRGEN Method for treating secondary hyperparathyroidism in CKD Apr, 2028

(5 years from now)

US11154509 EIRGEN Methods for controlled release oral dosage of a vitamin D compound Apr, 2028

(5 years from now)

US9498486 EIRGEN Method for controlled release oral dosage of a vitamin D compound Apr, 2028

(5 years from now)

US8778373 EIRGEN Methods for controlled release oral dosage of a vitamin D compound Apr, 2028

(5 years from now)

US9408858 EIRGEN Method for treating secondary hyperparathyroidism in CKD Apr, 2028

(5 years from now)

US9925147 EIRGEN Method for treating secondary hyperparathyroidism in CKD Apr, 2028

(5 years from now)

US8361488 EIRGEN Methods and compositions for controlled release oral dosage of a vitamin D compound Jul, 2028

(5 years from now)

US8426391 EIRGEN Treating vitamin D insufficiency and deficiency with 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3 Aug, 2028

(5 years from now)

US11253528 EIRGEN Stabilized modified release Vitamin D formulation and method of administering same Mar, 2034

(11 years from now)

US10357502 EIRGEN Stabilized modified release vitamin D formulation and method of administering same Mar, 2034

(11 years from now)

US9861644 EIRGEN Stabilized modified release vitamin D formulation and method of administering same Mar, 2034

(11 years from now)

US10300078 EIRGEN Stabilized modified release vitamin D formulation and method of administering same Mar, 2034

(11 years from now)

Drugs and Companies using CALCIFEDIOL ingredient

Treatment: Maintaining serum 25-hydroxyvitamin d at a level of at least 30 ng/ml with oral, sustained release 25-hydroxyvitamin d; Treatment of secondary hyperparathyroidism in patients with stage 3 or 4 chronic kidney disease using controlled release, oral 25-hydroxyvitamin d; Treating secondary hyperparathyroidism in stage 3/4 chronic kidney disease with sustained release 25-hydroxyvitamin d to reduce the patient's serum parathyroid hormone level while avoiding pth oversuppression; Use of extended release oral 25-hydroxyvitamin d3 in treating secondary hyperparathyroidism in adult patients having chronic kidney disease stage 3 or stage 4; Administration of 25-hydroxyvitamin d3 by controlled release; Use of controlled release 25-hydroxyvitamin d in treating secondary hyperparathyroidism in patients having chronic kidney disease; Treating secondary hyperparathyroidism in ckd with sustained release calcifediol to reduce the patient's serum parathyroid hormone level and cmax24hr/c24hr is reduced compared to bolus iv injection and immediate-release, oral dosing; treating secondary hyperparathyroidism in chronic kidney disease with sustained release 25-hydroxyvitamin d to reduce the patient's serum parathyroid hormone level and the sustained release is over at least 10 hours; treating secondary hyperparathyroidism in chronic kidney disease with sustained release 25-hydroxyvitamin d to reduce the patient's serum parathyroid hormone level and cmax is reduced compared to bolus iv injection and immediate-release, oral dosing; treating shpt in ckd with sustained release calcifediol to reduce serum parathyroid hormone level and change in serum concentration of calcifediol in dose interval is reduced compared to bolus iv injection and immediate-release, oral dosing; treating secondary hyperparathyroidism in ckd with sustained release calcifediol to reduce the patient's serum parathyroid hormone level and tmax is increased compared to bolus iv injection and immediate-release, oral dosing; Use of sustained release 25-hydroxyvitamin d in treating patients having 25-hydroxyvitamin d insufficiency or deficiency

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
0.03MG CAPSULE, EXTENDED RELEASE;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.